| Literature DB >> 32368284 |
Feng Du1, Zhiwei Sun1, Jun Jia1, Ying Yang1, Jing Yu1, Youwu Shi1, Bo Jia2, Jiuda Zhao3, Xiaodong Zhang1.
Abstract
An accurate estimation of prognosis of the esophageal carcinoma patients after surgery is urgently needed. Clinical nomogram has been developed to quantify risk by incorporating prognostic factors for individual patient. Based on the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2013, a total of 4566 patients were selected. Of those, 3198 patients were assigned to training set to construct the nomogram, which incorporated age, gender, histology, grade, T stage, N stage, nodes examined, radiation and chemotherapy. The calibration curve for probability of survival showed good agreement between prediction by nomogram and actual observation. The C-index of the nomogram was 0.71(95%CI 0.70-0.72), which was statistically higher than the TNM staging system. The results were then validated using bootstrap resampling and a validation set of 1368 patients in the SEER database. Besides, in the esophageal squamous cell carcinoma and esophageal adenocarcinoma subgroups, the nomogram discrimination was superior to the TNM staging system. It is likely that these results would play a supplementary role in the current staging system and help to identify the high risk population after surgery. © The author(s).Entities:
Keywords: Esophageal Neoplasms; Nomogram; Prognosis
Year: 2020 PMID: 32368284 PMCID: PMC7196250 DOI: 10.7150/jca.40767
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Figure 1Patients included in and excluded from study.
Demographics and Clinicopathologic Characteristics of Patients With non-metastatic esophageal carcinoma
| All cases | Training | Validation | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variables | N | % | N | % | N | % | |||
| 1709 | 37.4 | 1200 | 37.5 | 509 | 37.2 | ||||
| 1754 | 38.4 | 1221 | 38.2 | 533 | 39.0 | ||||
| 931 | 20.4 | 659 | 20.6 | 272 | 19.9 | ||||
| 172 | 3.8 | 118 | 3.7 | 54 | 3.9 | ||||
| 4129 | 90.4 | 2892 | 90.4 | 1237 | 90.4 | ||||
| 246 | 5.4 | 170 | 5.3 | 76 | 5.6 | ||||
| 186 | 4.1 | 131 | 4.1 | 55 | 4.0 | ||||
| 5 | 0.1 | 5 | 0.2 | 0 | 0.0 | ||||
| 3881 | 85.0 | 2736 | 85.6 | 1145 | 83.7 | ||||
| 685 | 15.0 | 462 | 14.4 | 223 | 16.3 | ||||
| 86 | 1.9 | 65 | 2.0 | 21 | 1.5 | ||||
| 657 | 14.4 | 455 | 14.2 | 202 | 14.8 | ||||
| 3541 | 77.6 | 2484 | 77.7 | 1057 | 77.3 | ||||
| 282 | 6.2 | 194 | 6.1 | 88 | 6.4 | ||||
| 3637 | 79.7 | 2553 | 79.8 | 1084 | 79.2 | ||||
| 929 | 20.3 | 645 | 20.2 | 284 | 20.8 | ||||
| 772 | 16.9 | 556 | 17.4 | 216 | 15.8 | ||||
| 1804 | 39.5 | 1260 | 39.4 | 544 | 39.8 | ||||
| 1990 | 43.6 | 1382 | 43.2 | 608 | 44.4 | ||||
| 1327 | 29.1 | 938 | 29.3 | 389 | 28.4 | ||||
| 729 | 16.0 | 521 | 16.3 | 208 | 15.2 | ||||
| 2256 | 49.4 | 1560 | 48.8 | 696 | 50.9 | ||||
| 254 | 5.6 | 199 | 6.2 | 75 | 5.5 | ||||
| 2871 | 62.9 | 2024 | 63.3 | 847 | 61.9 | ||||
| 981 | 21.5 | 684 | 21.4 | 297 | 21.7 | ||||
| 484 | 10.6 | 343 | 10.7 | 141 | 10.3 | ||||
| 230 | 5.0 | 147 | 4.6 | 83 | 6.1 | ||||
| 2748 | 60.2 | 1936 | 60.5 | 812 | 59.4 | ||||
| 1818 | 39.8 | 1262 | 39.5 | 556 | 40.6 | ||||
| 2989 | 65.5 | 2104 | 65.8 | 885 | 64.7 | ||||
| 1577 | 34.5 | 1094 | 34.2 | 483 | 35.3 | ||||
| 2328 | 51.0 | 1612 | 50.4 | 716 | 52.3 | ||||
| 2238 | 49.0 | 1586 | 49.6 | 652 | 47.7 | ||||
Multivariate Cox Analysis of the training cohort
| Variable | Cancer-specific survival | ||||
|---|---|---|---|---|---|
| HR | 95% CI | P value | |||
| <0.001 | |||||
| Ref | |||||
| 1.18 | 1.06 | 1.32 | |||
| 1.35 | 1.18 | 1.55 | |||
| 1.85 | 1.44 | 2.38 | |||
| 0.306 | |||||
| Ref | |||||
| 1.02 | 0.82 | 1.28 | |||
| 0.95 | 0.74 | 1.23 | |||
| 0.39 | 0.06 | 2.78 | |||
| 0.045 | |||||
| Ref | |||||
| 0.85 | 0.73 | 0.99 | |||
| <0.001 | |||||
| Ref | |||||
| 1.18 | 1.01 | 1.37 | |||
| <0.001 | |||||
| Ref | |||||
| 1.233 | 1.05 | 1.45 | |||
| 1.63 | 1.39 | 1.91 | |||
| 0.310 | |||||
| Ref | |||||
| 1.09 | 0.74 | 1.59 | |||
| 0.80 | 0.55 | 1.16 | |||
| 1.15 | 0.76 | 1.73 | |||
| <0.001 | |||||
| Ref | |||||
| 1.90 | 1.58 | 2.28 | |||
| 2.90 | 2.47 | 3.40 | |||
| 2.59 | 2.03 | 3.3 | |||
| <0.001 | |||||
| Ref | |||||
| 1.95 | 1.73 | 2.20 | |||
| 2.85 | 2.46 | 3.30 | |||
| 4.17 | 3.43 | 5.08 | |||
| <0.001 | |||||
| Ref | |||||
| 0.74 | 0.67 | 0.82 | |||
| 0.024 | |||||
| Ref | |||||
| 1.18 | 1 | 1.40 | |||
| <0.001 | |||||
| Ref | |||||
| 0.63 | 0.53 | 0.76 | |||
Figure 2Non-metastatic esophageal carcinoma survival nomogram. (To use the nomogram, an individual patient,s value is located on each variable axis, and a line is drawn upward to determine the number of points received for each variable value. The sum of these numbers is located on the Total Points axis, and a line is drawn downward to the survival axes to determine the likelihood of 3- or 5-year survival).
Figure 3The calibration curve for predicting patient survival at (A) 3 years and (B) 5 years in the training cohort and at (C) 3 years and (D) 5 years in the validation cohort. Nomogram-predicted probability of overall survival is plotted on the x-axis; actual overall survival is plotted on the y-axis.